Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05433116
Title Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Erlangen-Nuernberg Medical School

hypopharynx cancer

supraglottis squamous cell carcinoma

oral squamous cell carcinoma

oropharynx cancer


Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.